Page 36 - fbkCardioDiabetes_2017

12 Genesis Growth And Future of Cardiodiabetic Medicine

disease, drug and food interactions, comorbidity, as
Gene Gene well as genetic factors. Large variability related to
Region SNPs Population hypoglycemic drug therapy response is often
KCNQ1 11p15.4 rs2237897 Japanese encountered in the clinic. Poor therapeutic
11p15.4 rs2237895 Chinese outcomes may be caused by variability of individual

characteristics. Personalized medicine is an emerging
11p15.4 rs231362 European concept for treating diseases, which involves
11p15.4 rs2237892 Japanese determining specifi c information of a particular
patient and then prescribing specific treatment.
TCF7L2 10q25.2 rs7903146 European
Pharmacogenetics holds the promise of bringing
KCNJ11 11p15.1 rs5219 European personalized medicine to drug dosing decisions, to
reduce morbidity and mortality, and to improve life
11p15.1 rs5215 UK
quality for T2DM patients.
IRS1 2q36.3 rs7578326 European
Digital Cardiac Health
MTNR1B 11q14.3 rs1387153 European
Solutions that exist currently are portable ECG
IGF2BP2 3q27.2 rs4402960 European
recorders and Holter monitors but none provide real-
3q27.2 rs6769511 European time, beat-by-beat event information and have very
less recording time. They are very expensive and
CDKN2A/B 9p21.3 rs564398 UK
are heavy for the patient to attach to their body for
9p21.3 rs2383208 Japanese extended period of time. Sensory Health Systems use
latest advances in mobile technology and sensors to
9p21.3 rs10811661 European
provide a digital healthcare platform to keep patients
HHEX 10q23.33 rs1111875 European with heart conditions out of hospitals.
10q23.33 rs5015480 European
Remote Monitoring
PPARG2 3p25.2 rs1801282 European
India being the cardiac disease capital of the world
3p25.2 rs17036101 European and CVD’s being leading cause of deaths in the
country makes it first target market for the company.
individual patient only, and will not be inherited by The company’s platform consists of wearable
the patient’s offspring or later generations wireless health sensors that provide continuous
monitoring outside clinical settings with acceptable
2.Germ line gene therapy - sperm or eggs, are accuracy. The sensors and electrodes are designed
modified by the introduction of functional genes, keeping the patients comfort, convenience and other
which are integrated into their genomes. This would environment conditions in mind. It can be used at
allow the therapy to be heritable and passed on to home and on the go. It uses advanced data analytics
later generations
to provide real time diagnosis on the smart phone
Clinical Success since 2006 upon treatment of Retinal based on the sensed data and patient’s digital health
Disease, Inherited disorders & various Leukemias. record.

IDDM also responds well. Future will be for NIDDM
& Coronary Heart Disease. Vocal biomarkers: the future of diagnostic
medicine
Pharmacogenomics and Personalised Not long ago, scientists discovered vocal features
Medicine in every way imperceptible to humans. They also
found that the identification of such distinctive
Type 2 diabetes mellitus (T2DM) has reached characteristics might have a huge impact on setting
epidemic proportions worldwide and poses a up a diagnosis. Researchers labelled these features
considerable concern for public health. Although a “vocal biomarkers”. These can serve as a diagnostic
variety of pharmacological treatments is available, tool for your physician to indicate signs of illnesses
but response, doses, and tolerability to drugs are ranging from stress and depression to cardiovascular
highly variable and monotherapy often failed. A large diseases. 16
interindividual variability in drug response has been
noticed and contributing factors include age, sex, Vocal biomarkers will gain ground in 2017. Instead

GCDC 2017